Redbiotec, a Swiss biotechnology company, develops immunotherapies against Herpes and cancer

Our therapies are based on best-in-class proteins and microorganisms.

Track record of Redbiotec:

  • Deals closed with pharma companies in U.S., Asia and Europe (including Switzerland)
  • Trade sale of spin-off Redvax to Pfizer (press release) for its CMV vaccine program and a further undiclosed program.
  • Internationally recognized scientists as scientific advisors
  • Engineering and production of >100 novel proteins and protein complexes
  • First company having successfully developed stable CMV pentamer at >95% purity